Hong Kong skyline
Dicada | E+ | Getty pictures
Regencell Bioscience HoldingsA bioscience company based in Hong Kong without revenue is the latest speculative shares in overseas that attracts an unusual increase in commercial demand.
Regencelle's shares, which says that it develops traditional Chinese herbal treatments to treat the attention deficit hyperactivity disorder and autism, has more than tripled on Monday. At the end of Monday, Regencelle, which was founded in 2014 and had been traded on Nasdaq under the ticker 'RGC' since 2021, had a market capitalization of $ 29.7 billion.
The share continued to jump on Tuesday and more than 25%. The company's previous performance is also from the charts, since it rose by more than 58,000% in 2025. The current market value of 36 billion US dollars Lululemon, Ebay and Kraft Heinz. The stocks acted for Pennies in the last one year.
Stock Diagram -iconstock -Igram -Symbol
Regencell Bioscience Holdings in 2025.
Regencell is the latest example of a speculative international share that draws attention to during summer trade. In August 2022, for example, Amtd DigitalA fintech company based in Hong Kong, rose by 126%and briefly gave it a market value greater than Coca-Cola And Bank of America.
At the beginning of this month, Regencelle explained the shareholding of the shares exclusively “to improve liquidity on the market for the company's regular shares and the achievement of shares for investors”. Share division do not change anything fundamentally in relation to a company.
Regencells Surge also focused on alternative medication after Robert F. Kennedy Jr. in February as secretary of the US Ministry of Health and Human Services. Kennedy, an vaccine skeptic, has taken steps to discourage routine imperies in the United States. Last week, all members of a committee remove the centers for the control and prevention of diseases on vaccines.
Regcell's share often makes large one -day fluctuations. For example, the stocks rose by around 30% on March 21st before they fall by 30% on the following trading day.
Obscure treatments, zero revenue
Despite the wild tip in the existing existence, there is little known about the effectiveness and marketing of the treatments of Regcell for ADHD and autistic spectrum disorders.
Regcell's business focuses on a proprietary traditional Chinese medical formula (TCM), which was developed in a partnership with TCM practitioner Sik-Kee au using his “Sik-Kee au TCM brain theory”. Sik-Kee Au is the father of the Regcell Chief Executive Officer Yat-Gai Au, the company announced in an explanation of 2022.
The CEO controls 86.24% of the total number of outstanding shares, according to Factset.
Three fluid-based candidates based on fluid, orally shaped TCM formulas, claim to tackle light, moderate and serious illnesses and contain only natural ingredients such as so-called “detoxification herbs”, herbs the blood circulation and digestive herbs.
“These TCM formulas form the basis of our TCM product candidates that we want to develop and commercialize for the treatment of ADHD and ASD,” says Regcell's website.
In his last annual report, which was submitted last October, Regencell said that it did not generate income nor submitted an official approval of his TCM formulas. For the financial years, which ended June 2024 and 2023, Regencelle recorded a total of $ 4.36 million or $ 6.06 million according to a submission to the SEC.
“We have not achieved any income from candidates for TCM formulas or applied for official approvals, still distribution functions or experiences or granted patents or upcoming patent applications and may never be profitable,” says the submission.
Regencell did not answer a CNBC request for comment.
The latest patient study in Regencell on November 15, 2023 said that 28 patients were treated in a second effectiveness study over a period of three months and, according to the company's website, showed an improvement in the symptoms of ADHD and ASD.
In an earlier case, Regencelle said in a press release from 2021 that it treated a dozen patients with suspected or confirmed covid-19 cases using a modified version of the modified proprietary cold and flu-TCM formula from AU. Regarded what was described as an improvement in the COVID conditions caused Regcelle to form a joint venture with Honor Epic Enterprises in September 2021 in order to carry out further tests and to commercialize the company's covid treatment in countries of the Association of Southeast Asian nations.
Online sums
The share has attracted little chattering on social media in recent years. These comments that have been made interpret both the enthusiasm of retail dealers – and skepticism.
A user on the Reddit page “R/Shortsqueze” wrote on Monday that Regencell “acted like a Meme coin. Bought a little to see what happens, and it fell right after Lol.” Another user said in a post three months ago: “I page RGC every day for a little profit.” The stock rose by 1,360%in May alone.
At LinkedIn in May an investor said that he could “stop laughing” after reading the company description. Another contribution from a user in the pharmaceutical industry, according to his profile, said Regencell last week to “Share that” no official news or catalysts “after his increase in May. Another LinkedIn user last month commented: “China, low volume and no official news, bizarro.”
On X, a user wrote in a Monday contribution: “For #completebullsh__Companyoftheyear I nominate rain cell.”
– Scott Schnipper from CNBC contributed the reporting.